Glenmark Pharmaceuticals Ltd Q1 FY2027 Concall Summary

Key Takeaways

• Strong Q1, broad-based growth: Consolidated revenue grew 23.1% YoY, with base business (ex-ISB-2001 deferred income) growing north of 18%, driven by India, North America, and Emerging Markets.
• India outperformance anchored by oncology: India formulations grew 15.5% primary, 18.1% secondary, significantly ahead of IPM; Tevimbra and Brukinsa contributed over ₹100 crores in their first 12 months.
• North America respiratory ramp is the near-term catalyst: Revenue grew 41.1% YoY; Flutie 44 launched with partial-quarter benefit, and management expects at least 2–3 more respiratory approvals in H2 FY27.
• Margins under cost pressure, full-year guide held: Geopolitical cost headwinds on API and logistics expected to persist for at least 2 quarters, but management remains comfortable achieving 21%–22% full-year margins.
• What to watch next quarter: Pace of North America respiratory approvals and launches, trajectory of branded Europe as it transitions toward a ~60% branded mix, and whether cost pressures begin to ease as guided.

India Business: Volume-Led Outperformance

• Broad therapy leadership: Core therapies drove growth with cardiovascular at ~15%, chronic respiratory over 25%, and dermatology performing well; the diabetes franchise, previously declining, is turning around on semaglutide, tracking at ₹20–₹25 crores annualized.
• Growth composition: Volume contributed ~6%–7%, new products ~3%, and value ~3%–4%, reflecting high competitive intensity that limits price-led growth.
• Oncology building a material franchise: Tevimbra and Brukinsa, partnered with BeOne, crossed ₹100 crores in first-year sales; Aumolertinib and Trastuzumab Rezetecan launches expected from H2 FY27, with the three-brand portfolio projected to deliver almost ₹60 crore over 5–6 years.
• Consumer care momentum: GCC primary sales grew 28% YoY, led by CANDID (30%+ growth), SCALPE, and BONTRESS; LA SHIELD delivered mid-single-digit growth.
• Field force expansion continues: The company adds 300–400 MRs every year consistently; oncology sales force already in place in India, requiring no further expansion for upcoming launches.

Glenn Saldanha: "India is a very strong franchise for us. And I think if you are to model it going forward, you can easily assume that we will have between 12%-15% growth on a consistent basis from here on for the entire India business."

North America: Respiratory Launches Driving the Recovery

• Respiratory approvals stacking up: Fluticasone Propionate 44 mcg (generic Flovent HFA) received first ANDA approval with CGT designation and 180-day exclusivity; Fluticasone Propionate Nasal Spray OTC also approved; Flutie 44 realized about half a quarter benefit in Q1, with full-quarter benefit expected in Q2.
• Pipeline visibility: Two additional differentiated MDI ANDAs filed: Fluticasone Propionate 110 mcg (generic FloVent 110 mcg) and Ipratropium Bromide Inhalation Aerosol (generic ATROVENT); management anticipates at least 2 of these 3 products receiving approval in H2 FY27.
• Injectables building for next year: Monroe facility received EIR with VAI classification; Fulvestrant injection relaunched from Monroe; differentiated injectables expected to start contributing next year.
• RYALTRIS US commercialization initiated: End-to-end commercialization underway, with Glenmark leading brand strategy, market access, and customer engagement.
• 9 products launched in Q1: Including Methylene Blue Injection, Sodium Phosphates Injection, Vancomycin Injection, Clonazepam Injection, Progesterone Vaginal Inserts, and Calcium Gluconate Injection.

Europe: Transitioning the Mix Toward Branded

• Growth reset underway: Europe grew 11.9% YoY in Q1; after four years as the fastest-growing geography, the region is transitioning its portfolio toward branded respiratory and dermatology, with FY27 expected to finish at high single-digit growth.
• Branded mix ambition: Branded products currently represent ~30% of Europe revenue; management targets ~60% over the next 5 years, with branded launches expected to drive a return to double-digit growth from FY28.
• Winlevi rollout expanding: Launched in UK in Q1 FY26; received MA approval in European markets in October; launched across CEE, Spain, Nordic countries, and Portugal during Q1; adoption is just beginning.
• Respiratory momentum: Market share increases across MDI and nasal sprays; additional 2–3 respiratory launches expected in the next 12–18 months.
• RYALTRIS global footprint: Global secondary sales growth upwards of 40% YoY; approved in China and Thailand in Q4, launched by regional partners; expected to launch in 10 markets over the next few quarters, including Brazil in H2 FY27.

Glenn Saldanha: "This year we'll finish probably at high single-digit for our European business. However, I think as these branded launches start gaining scale, right, we will get back to double-digit growth from next year, right, for our European business."

Innovative Pipeline: Oncology Anchors the Long-Term Story

• Aumolertinib: Approved in UK in June 2025; Hansoh received MA approval in European markets in Feb 2026; first commercial launch anticipated in India and all emerging markets starting H2 FY27; positioned as a big product in non-small cell lung cancer.
• Trastuzumab Rezetecan: Phase 3 trial in platinum-resistant ovarian cancer initiated in India in June 2026; first wave of MA applications expected to begin in Q2 FY27; management believes it can be a big product and will place Glenmark among oncology leaders in India within 5 years.
• Envafolimab (QiNHAYO): Global multicenter Phase 3 study initiated in neoadjuvant/adjuvant NSCLC; first commercial launch expected in FY28.
• ISB-2001: Multi-center Phase 1/2 combination study in multiple myeloma initiated; will leverage the same oncology infrastructure being built for the partnered portfolio when available; described as "the big one" over the next 5–10 years.
• ISB-2301: Described as a "super exciting asset," a penta-specific targeting both NK cells and T cells with tumor antigens; IND submission intended later this year; partnering discussions will wait until at least some human clinical data and proof-of-concept.
• R&D spend steady: Overall R&D expected to continue around 7%–8% of revenue; IGI spend around $70 million, covering ISB-2301 Phase 1 and all anticipated clinical trials over the next 2–3 years.

Glenn Saldanha: "2301 is a super exciting asset, right? I mean, we've, you know, it's a penta-specific which globally, you know, puts us at the world stage in terms of innovation, right? No one has ever bought, you know, tried to target both NK cells as well as activate T cells, right, along with these tumor antigens. So it's a very, very novel concept overall."

Margins & Costs: Headwinds Managed, Full-Year Guide Intact

• Gross margin held: Improved product and geographical mix helped maintain gross margin despite increased API costs and logistics expenses from the ongoing geopolitical situation.
• Operating margin impact: Reinvestment in the base business and innovative business expansion, coupled with higher shipment and logistics costs, weighed on operating margins.
• Cost pressure duration: Management sees cost pressure continuing for at least 2 quarters and will attempt to mitigate through product and geographical mix; full-year margin guidance of 21%–22% remains comfortable.
• Other income uplift: Working capital initiatives generated incremental income through interest rate arbitrage, with associated interest income clubbed under other income in the P&L.
• Gross interest costs: Rose mainly on account of higher lease expenses, bank commitment charges, and various interest arbitrage items.
• Balance sheet discipline: Management remains committed to maintaining a gross debt zero position; net working capital full-year guidance is 115 days, and the company is currently well below that.

Anurag Mantri: "I think in the future quarter also, at least 2 quarters, we can -- we see the pressure coming up on because of this, and we'll try our best to mitigate through the product and geographical mix."

Litigation & Risk: Provisions Largely Behind

• Major provisions taken: Most major litigations have already been provided for; the state AGs settlement provision was taken in Q4 and the settlement is done; DPPs have been settled.
• Remaining exposure limited: EPP and one more group remain outstanding but are not expected to be very significant incrementally; from a P&L perspective, all known litigations have been provided for.
• Cash flow timing: Litigation-related cash outflows will occur over the next two years, with the P&L impact already absorbed.
• Execution risk this year: Management characterized risk as relatively low, describing the remainder of the year as a matter of execution.
• BioCryst / ISB-830 uncertainty: Management has no visibility into BioCryst's further development plans following their recent acquisition and is still trying to determine next steps; STAR-310 (ISB-830 backup) has completed Phase 1.

Anurag Mantri: "as a P&L perspective, we have provided all the litigations as of known today."

Guidance & Commitments

Key Metrics